Answers are grounded in this paper and cite their sources.
Reliable comparison of antioxidant potency is complicated by the strong dependence of measured activity on assay conditions. ABTS, DPPH, superoxide, lipid-peroxidation, and hydroxyl-radical tests capture different chemical environments and reaction mechanisms, making a single global model potentially misleading. We therefore evaluated a class-conditional quantitative structure-activity relationship framework for jointly predicting assay identity and antioxidant potency. The curated dataset comprised 1,059 compound-assay records from 898 standardized compounds and 330 Bemis-Murcko scaffolds. Models used 102 RDKit descriptors, 14 classical indices, and 14 geometric-arithmetic indices, with all preprocessing restricted to the training folds. Robustness was examined through repeated compound-grouped cross-validation, scaffold-grouped testing, descriptor-block ablation, architecture controls, response permutation, residual diagnostics, endpoint sensitivity, and applicability-domain analysis. Conditional XGBoost achieved a compound-grouped classification accuracy of \(0.718± 0.027\) and known-assay regression performance of \(R^2=0.718± 0.053\) . A Morgan ECFP4 random-forest comparator gave the best compound-grouped regression result ( \(R^2=0.739± 0.065\) ), but its performance declined under scaffold separation ( \(R^2=0.472± 0.303\) ). The connectivity-index blocks did not significantly improve the RDKit-only models after Holm adjustment. These findings support assay-aware modeling for related chemical structures, while showing that predictions for unfamiliar scaffolds require applicability-domain screening and prospective validation.
No takes yet. Share an insight, caveat, or question.
Alhaj et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: